Time-perspective in cardiovascular risk of NSAID use after first-time myocardial infarction

Current Opinion in Cardiology

Volumn 28, Issue 6, 2013, Pages 683-688

  Olsen, Anne Marie Schjerning ^a   Gislason, Gunnar H ^a,b,c   Fosbøl, Emil L ^a,d,e  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Mortality; myocardial infarction; NSAIDs; prognosis; selective cyclooxygenase 2 inhibitors

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; COLLAGEN; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NAPROXEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PROSTACYCLIN; PROSTAGLANDIN H2; ROFECOXIB; THROMBIN; THROMBOXANE A2; VALDECOXIB;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS SURGERY; DEATH; DRUG SAFETY; HEART INFARCTION; HUMAN; LAW; MEDICAL SOCIETY; MORTALITY; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHORT COURSE THERAPY; TOXICITY; TREATMENT DURATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MYOCARDIAL INFARCTION; RISK FACTORS; TIME FACTORS;

EID: 84886093087     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283652dad     Document Type: Review

References (62)

1. Fosbol EL, Gislason GH, Jacobsen S, et al. The pattern of use of nonsteroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiol Drug Saf 2008; 17:822-833.
2. Arellano FM, Yood MU, Wentworth CE, et al. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription nonsteroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiol Drug Saf 2006; 15:861-872. (Pubitemid 44941639)
3. Fosbol EL, Gislason GH, Jacobsen S, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009; 85:190-197.
4. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343:1520-1528; 2 p following 1528.
5. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092-1102. (Pubitemid 40365350)
6. Brophy JM, Levesque LE, Zhang B. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart 2007; 93:189-194. (Pubitemid 46180292)
7. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and non-selective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006; 113:2906-2913. (Pubitemid 44297231)
8. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009; 169:141-149.
9. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and nonselective nonsteroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365:475-481. (Pubitemid 40215729)
10. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005; 165:978-984. (Pubitemid 40638117)
11. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296:1633-1644. (Pubitemid 44511610)
12. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352:1081-1091. (Pubitemid 40365349)
13. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071-1080. (Pubitemid 40365348)
14. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115:1634-1642. (Pubitemid 46648649)
15. Hensrud DD, Engle DD, Scheitel SM. Underreporting the use of dietary supplements and nonprescription medications among patients undergoing a periodic health examination. Mayo Clin Proc 1999; 74:443-447. (Pubitemid 29207140)
16. Teeling M, O'Connor H, Feely J, Bennett K. What therapies have replaced rofecoxib in Ireland? Br J Clin Pharmacol 2007; 64:536-541. (Pubitemid 47404306)
17. Sorensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374:1967-1974.
18. Cryer B, Kimmey MB. Gastrointestinal side effects of nonsteroidal anti-inflammatory drugs. Am J Med 1998; 105:20S-30S. (Pubitemid 28378014)
19. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12:1063-1073. (Pubitemid 28418937)
20. Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343:834-839.
21. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional nonaspirin nonsteroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55:1731-1738. (Pubitemid 44893570)
22. Lanas A, Baron JA, Sandler RS, et al. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology 2007; 132:490-497. (Pubitemid 46274654)
23. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247-1255.
24. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:241-249.
25. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115:787-796.
26. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005; 112:759-770. (Pubitemid 41099056)
27. Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368:1771-1781. (Pubitemid 44739003)
28. Sibbald B. Rofecoxib (Vioxx) voluntarily withdrawn from market. CMAJ 2004; 171:1027-1028.
29. Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008; 372:1756-1764.
30. Nissen SE. Adverse cardiovascular effects of rofecoxib. N Engl J Med 2006; 355:203-204; author reply 205.
31. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006; 131:1674-1682. (Pubitemid 44958508)
32. Lagakos SW. Time-to-event analyses for long-term treatments: the APPROVe trial. N Engl J Med 2006; 355:113-117. (Pubitemid 44050391)
33. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus nonselective nonsteroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363:1751-1756. (Pubitemid 38698377)
34. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162:1099-1104. (Pubitemid 34522394)
35. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332:1302-1308.
36. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286:954-959. (Pubitemid 33010342)
37. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxy-genase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125:1481-1492. (Pubitemid 36759251)
38. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006; 27:1657-1663. (Pubitemid 44025350)
39. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330:1366.
40. Strand V. Are COX-2 inhibitors preferable to nonselective nonsteroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 2007; 370:2138-2151. (Pubitemid 350296305)
41. Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 52:1628-1636.
42. Levesque LE, Brophy JM, Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ 2006; 174:1563-1569. (Pubitemid 43829511)
43. Andersohn F, Suissa S, Garbe E. Use of first-and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006; 113:1950-1957.
44. Dai C, Stafford RS, Alexander GC. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med 2005; 165:171-177.
45. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165:490-496. (Pubitemid 40344379)
46. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364:2021-2029. (Pubitemid 39593078)
47. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011; 8:e1001098.
48. Fosbol EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 2010; 3:395-405.
49. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of nonster-oidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342:c7086.
50. Olsen AM, Fosbol EL, Lindhardsen J, et al. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients: a nationwide study. PLoS One 2013; 8:e54309.
51. Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006; 114:1028-1035. (Pubitemid 44358879)
52. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116:4-15. (Pubitemid 43121782)
53. Grosser T, Yu Y, Fitzgerald GA. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med 2010; 61:17-33.
54. Lipsky LP, Abramson SB, Crofford L, et al. The classification of cyclooxy-genase inhibitors. J Rheumatol 1998; 25:2298-2303.
55. Warner TD, Vojnovic I, Giuliano F, et al. Cyclooxygenases 1, 2, and 3 and the production of prostaglandin I2: investigating the activities of acetaminophen and cyclooxygenase-2-selective inhibitors in rat tissues. J Pharmacol Exp Ther 2004; 310:642-647. (Pubitemid 38988909)
56. Minuz P. Nonsteroidal anti-inflammatory drugs and cardiovascular risk: is prostacyclin inhibition the key event? J Am Coll Cardiol 2008; 52:1637-1639.
57. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011; 123:2226-2235.
58. Waksman JC, Brody A, Phillips SD. Nonselective nonsteroidal antiinflam-matory drugs and cardiovascular risk: are they safe? Ann Pharmacother2007; 41:1163-1173. (Pubitemid 47122553)
59. Olsen AM, Fosbol EL, Lindhardsen J, et al. Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first time myocardial infarction: a nationwide cohort study. Circulation 2012;126:1955-1963.
60. Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death inpatients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005; 352:2581-2588. (Pubitemid 41007844)
61. Statens Serum Institut. medstat.dk. http://www.medstat.dk/da/viewData- Tables/.[Accessed 15 May 2013]
62. McGettigan P, Henry D. Use of nonsteroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med 2013;10:e1001388.